Abstract
Systemic immunosuppressants are used off-label to treat paediatric patients with moderate-to severe atopic dermatitis (AD) for whom topical treatment has failed. A large real-life cohort of paediatric patients with AD treated with systemic immunosuppressive treatments is described in order to guide dermatologists’ prescribing practices when faced with a moderate to-severe AD paediatric patient who has failed or has a contraindication to topical treatment, phototherapy, biological agents or Janus kinase inhibitors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
